In addition, XLEP can upregulate the ratio of M1/M2 macrophages by inhibiting autophagy to achieve the therapeutic effect for drug-resistant EGFR-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.